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Table 1
Daily Micafungin Antifungal Prophylaxis Results
Observations Number (%) or Median (Range)
Total patients 28
Duration (days) 37 (3-94)
Average dose - start (mg/kg/day) 2.1 (0.8-4.3)
AST
Baseline elevation 7 (25)
End elevation 7 (25)
Increase  2x baseline 17 (61)
ALT
Baseline elevation 11 (39)
End elevation 10 (36)
Increase  2x baseline 19 (68)
Total Bilirubin
Baseline elevation 0
End elevation 4 (14)
Increase  2x baseline 24 (86)
Creatinine
Baseline elevation 1 (4)
End elevation 1 (4)
Increase  2x baseline 10 (36)
Table 1
Alternate day Micafungin Antifungal Prophylaxis: Results
Observations Number or Median (Range)
Total number of patients 33
Total weeks of alternate day
Micafungin
10 (4-28)
Liver proﬁle trends during
Micafungin prophylaxis
Baseline ALT 49 (15-164)
Baseline AST 51 (15-1080)
Baseline direct bilirubin 0.1 (0-4.3)
Highest ALT 138 (26-491)
Highest AST 105 (37-900)
Highest direct bilirubin 0.2 (0-9)
End of therapy ALT 98 (20-190)
End of therapy AST 52 (18-156)
End of therapy direct bilirubin 0.1 (0.1-8.9)
Breakthrough fungal infection 2
Patient 1 Candida albicans fungal esophagitis -
conﬁrmed by culture
Patient 2 Line infection - culture positive for
Candida glabrata
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Background: Disseminated fungal infection is a major cause
of morbidity and mortality in children undergoing HCT.
Prophylaxis with amphotericin B can be limited by renal
toxicity. Oral triazoles can be limited by poor absorption,
large interindividual pharmacokinetic (PK) variability, and
hepatic toxicity, leading to interruptions in therapy and
breakthrough infections. Micafungin has potential advan-
tages, due to its better safety proﬁle, speciﬁcally in terms of
hepatic and renal toxicity, and lack of drug-drug interactions
with common medications used in the HCT setting.
Both animal and adult human data suggest that alternate
day dosing schedule can be effective. In a PK study in pedi-
atric HCT patients, we have previously shown detectable and
protective Micafungin levels at 48 hours after the dose
(Mehta et al, 2010). Here we report our clinical experience of
use of alternate day micafungin (3 mg/kg) in high risk
pediatric patients undergoing HCT.
Methods: A total of 33 infants and children with various
hematological and immune deﬁciency disorders undergoing
HCT were reviewed retrospectively. The median age was 5
years (range 0.5-20). None of the patients had a history of
prior fungal infection.
Results: Results are described in Table 1. Eleven patients
were started on alternate day Micafungin after sustaining
liver dysfunction from voriconazole, liver graft vs. host
disease (GVHD), disseminated viral infection and/or veno-
occlusive disease. Three patients developed liver
dysfunction while on alternate day micafungin from similar
causes. In all these patients, continuation of micafungin did
not worsen liver dysfunction, which in fact improved in
most patients over time. Two patients developedbreakthrough fungal infection during alternate day
micafungin prophylaxis. One patient had been on
micafungin for 8 weeks and another for 14 weeks at the
time of developing breakthrough candida line infection and
esophagitis respectively. Of note, both these patients had
refractory liver and gastrointestinal GVHD and were
signiﬁcantly immunocompromised from multiple immune
suppressive therapies for their GVHD.
Conclusion: We conclude that, alternate day micafungin
prophylaxis is safe and well tolerated; speciﬁcally even in
patients with baseline liver dysfunction, without additional
liver toxicity. This provides a simple prophylaxis regimen
that can be administered for prolonged duration to patients
undergoing HCT even on an outpatient basis.297
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Introduction: Historically, diagnosis of enigmatic pulmo-
nary disease after hematopoietic cell transplant (HCT) has
required lung biopsy. Recent improvements in laboratory
diagnostics and therapies for fungal infections have led to
changes in how clinicians approach pulmonary abnormali-
ties. We examined temporal trends in the use of lung biopsy
after HCT.
Methods: We retrospectively reviewed patients who
underwent their ﬁrst allogeneic HCT at the Fred Hutchinson
Cancer Research Center between the years 1993-1997 and
2003-2007. Data on lung biopsies were abstracted from
a prospectively collected database of all recipients from these
two cohorts (NEJM 2010). Outcome datawere analyzed using
Fisher's exact test. Hazards for lung biopsy for the two
cohorts were determined using a Cox-proportional hazards
model with death and relapse considered competing risks.
Results: A total of 50/1418 (3.5%) patients underwent 52
post-HCT surgical lung biopsies during 1993-1997 compared
